- Home
- ACB vs ZNTL Comparison
ACB vs ZNTL Comparison
Compare ACB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | ZNTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.4M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACB | ZNTL |
|---|---|---|
| Price | $4.57 | $1.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | ★ 2.8M | 758.1K |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $263,570,704.00 | $26,865,000.00 |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.89 | N/A |
| 52 Week Low | $3.42 | $1.01 |
| 52 Week High | $6.91 | $3.33 |
Technical Indicators
Market Signals| Indicator | ACB | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 47.91 |
| Support Level | $4.41 | $1.33 |
| Resistance Level | $6.36 | $1.46 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 8.04 | 33.33 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.